Core Insights - Dexcom presented breakthrough outcomes for Type 2 diabetes management and outlined its product roadmap at the ATTD 2026 conference, emphasizing the need for continuous glucose monitoring (CGM) to become standard care for all Type 2 diabetes patients, including those not on insulin therapy [1][2] Group 1: Product Features and Innovations - Dexcom showcased new registry study data indicating that long-term use of Dexcom G7 supports weight management and lowers A1C levels for non-insulin-treated Type 2 diabetes patients, highlighting the importance of CGM access for this demographic [1] - The company introduced its upcoming product features during the conference, including advancements in Dexcom G7 and Dexcom ONE+, as well as a new health and wellness product line called Stelo [1] - Dexcom's commitment to innovation includes the introduction of the Dexcom Academy, an education platform for healthcare professionals, which is currently available in several countries with plans for further expansion [1][2] Group 2: Clinical Evidence and Impact - A multi-center primary care registry study revealed that after one year of using Dexcom G7, non-insulin-treated Type 2 diabetes patients experienced significant improvements in A1C and weight management, reinforcing the benefits of CGM [1] - New evidence presented at the conference indicated that Dexcom CGM use is associated with reductions in diabetic ketoacidosis (DKA)-related hospitalizations and emergency room visits for both children and adults with Type 1 diabetes [1] - A prospective study demonstrated that Dexcom Smart Basal was safe and effective for optimizing basal insulin therapy in Type 2 diabetes patients, showcasing the technology's versatility [1] Group 3: Educational Initiatives - Dexcom introduced the first consensus-based CGM competency framework aimed at providing healthcare professionals with a structured approach to delivering CGM support, which will be utilized in the Dexcom Academy [1] - The company hosted symposiums at the conference to discuss the clinical implications of its technology and the benefits of early CGM use in prediabetes and Type 2 diabetes management [1]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported worldwide revenue of $1.26 billion, a 13% increase from $1.11 billion in Q4 2024, with organic growth at 12% [17] - U.S. revenue reached $892 million in Q4 2025, up 11% from $803 million in Q4 2024 [17] - International revenue grew 18% to $368 million in Q4 2025, with organic growth at 15% [18] - Gross profit for Q4 was $799.8 million, representing 63.5% of revenue, an increase from 59.4% in Q4 2024 [19] - Operating income was $331.5 million, or 26.3% of revenue, compared to $209.5 million, or 18.8% of revenue, in Q4 2024 [20] - Adjusted EBITDA for Q4 was $422.2 million, or 33.5% of revenue, up from $300.1 million, or 27.0% of revenue, in Q4 2024 [20] - The company closed the quarter with approximately $2 billion in cash and cash equivalents, indicating strong financial flexibility [21] Business Line Data and Key Metrics Changes - The rollout of the Dexcom G7 15-day system has received positive feedback, enhancing customer experience and potentially increasing market share [8][9] - The company is focusing on improving customer experience through new digital support systems and AI integration [9][10] - The early access launch of Dexcom Smart Basal aims to improve outcomes for Type 2 diabetes management [10] Market Data and Key Metrics Changes - International markets, particularly Germany, the UK, and France, showed strong growth, with France being one of the fastest-growing markets due to Type 2 access expansion [18] - The company plans to expand its CGM product portfolio in international markets in 2026, targeting new segments [14] Company Strategy and Development Direction - The company aims to be the premier glucose sensing solution, focusing on sensor accuracy, reliability, and connectivity [7][8] - Strategic priorities include enhancing customer experience, expanding international market share, and driving growth through product innovation [12][14] - The company is preparing for an Investor Day in May 2026 to provide further outlook details [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in metabolic health and the impact of CGM technology on patient outcomes [28] - The company anticipates total revenue for 2026 to be between $5.16 billion and $5.25 billion, reflecting growth of 11%-13% [22] - Management highlighted the importance of maintaining strong category growth and expanding CGM access globally [23] Other Important Information - The company has successfully managed supply chain challenges, leading to improved gross margins and reduced sensor deployment issues [15] - The launch of the new patch technology is expected to enhance customer experience across the product portfolio [11] Q&A Session Summary Question: Discussion on glucose journey and market potential - Management believes the company is in the early stages of addressing metabolic health and sees significant growth opportunities, especially with potential Medicare coverage for Type 2 non-insulin users [26][28] Question: CMS proposal for Type 2 non-insulin coverage - Management is optimistic about upcoming CMS coverage decisions and expects to see positive outcomes from ongoing clinical trials [32][35] Question: Impact of the 15-day product on margins and market expansion - The 15-day product is expected to contribute to margins over time, with significant opportunities for international market expansion [38][41] Question: Operating expenses and investment in manufacturing - The increase in operating expenses is primarily due to investments in the new Ireland manufacturing facility, which will enhance production capabilities [46][48] Question: Utilization rates among different user segments - Utilization rates remain stable across various user segments, with high engagement expected to drive further growth [52][54] Question: Revenue outlook and new patient dynamics - Management provided insights into the factors influencing revenue growth, emphasizing the importance of patient retention and utilization [60][62] Question: Strengthening U.S. sensor uptake trends - Improved sensor deployment and the launch of new products have positively impacted sell-through trends, contributing to stable user retention [68][70] Question: Pricing dynamics with potential Medicare unlock - Management discussed the stable pricing environment and the impact of competitive bidding processes on future pricing strategies [75][78] Question: International growth strategy and competition - The company aims to close the revenue gap with competitors by expanding its product portfolio and increasing market penetration in international markets [82][84]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported worldwide revenue of $1.26 billion, a 13% increase from $1.11 billion in Q4 2024, with organic growth at 12% [17] - U.S. revenue reached $892 million in Q4 2025, up 11% from $803 million in Q4 2024 [17] - International revenue grew 18% to $368 million in Q4 2025, with organic growth at 15% [18] - Gross profit for Q4 was $799.8 million, representing 63.5% of revenue, an increase from 59.4% in Q4 2024 [19] - Operating income was $331.5 million, or 26.3% of revenue, compared to $209.5 million, or 18.8% of revenue in Q4 2024 [20] - Adjusted EBITDA for Q4 was $422.2 million, or 33.5% of revenue, up from $300.1 million, or 27.0% of revenue in Q4 2024 [20] - The company closed the quarter with approximately $2 billion in cash and cash equivalents, indicating strong financial flexibility [21] Business Line Data and Key Metrics Changes - The rollout of the Dexcom G7 15-Day system has received positive feedback, enhancing customer experience and potentially increasing market share [8][9] - The company is focusing on expanding its product portfolio, including the introduction of Stelo and a new CGM system in international markets by 2026 [14] Market Data and Key Metrics Changes - The international business showed particular strength in Germany, the United Kingdom, and France, with France being one of the fastest-growing markets due to Type 2 access expansion [18] - The company anticipates that international market opportunities could surpass the U.S. market in the future [14] Company Strategy and Development Direction - The company aims to be the premier glucose sensing solution, focusing on improving sensor accuracy, reliability, and connectivity [8] - A strategic priority is to enhance customer experience across all stakeholders, including prescribers and caregivers, through new digital support systems and AI integration [9] - The company plans to expand its international market share by increasing awareness and access to CGM technology globally [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in metabolic health management, particularly with upcoming Medicare coverage for Type 2 non-insulin users, which could provide access to approximately 12 million people [28] - The company expects total revenue for 2026 to be in the range of $5.16 billion to $5.25 billion, reflecting growth of 11%-13% [22] - Management highlighted the importance of maintaining gross margin improvements and operational efficiencies while investing in new product launches and manufacturing capabilities [23] Other Important Information - The company has surpassed $1 billion in free cash flow for the first time in 2025, indicating strong cash generation capabilities [22] - An Investor Day is planned for May 2026 to provide further details on the company's outlook [16] Q&A Session Summary Question: Discussion on the glucose journey and potential coverage - Management believes the company is in the early stages of addressing metabolic health issues, with significant growth opportunities as coverage expands for Type 2 non-insulin users [26][28] Question: CMS proposal for Type 2 non-insulin coverage - Management is optimistic about upcoming CMS coverage decisions and expects to see results from a randomized control trial in mid-2026 [32][35] Question: Impact of the 15-Day product on margins and new markets - The 15-Day product is expected to contribute to margins over time, with significant opportunities for international expansion [38][41] Question: Operating expenses and investment in manufacturing - The increase in operating expenses is primarily due to investments in the new Ireland manufacturing facility, which will enhance future production capabilities [46][49] Question: Utilization rates among different user segments - Utilization rates remain stable across various user segments, with high rates observed in Type 1 and Type 2 insulin users [52][54] Question: 2026 revenue outlook and new patient dynamics - Revenue growth will depend on patient retention, utilization, and pricing, with expectations for continued strong performance in new patient additions [60][62] Question: International growth strategy and competition - The company aims to close the revenue gap with competitors by expanding coverage and product offerings in international markets [82][84]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported worldwide revenue of $1.26 billion, a 13% increase from $1.11 billion in Q4 2024, with organic growth at 12% [15][16] - U.S. revenue reached $892 million in Q4 2025, up 11% from $803 million in Q4 2024 [15] - International revenue grew 18% to $368 million in Q4 2025, with organic growth at 15% [16] - Gross profit for Q4 was $799.8 million, representing 63.5% of revenue, an increase from 59.4% in Q4 2024 [17] - Operating income was $331.5 million, or 26.3% of revenue, compared to $209.5 million, or 18.8% of revenue, in Q4 2024 [18] - Net income for Q4 was $265.1 million, equating to $0.68 per share [18] - The company closed the quarter with approximately $2 billion in cash and cash equivalents, indicating strong financial flexibility [18] Business Line Data and Key Metrics Changes - The rollout of the Dexcom G7 15-day system has received positive feedback, enhancing customer experience and potentially increasing market share [6][12] - The company is focusing on improving customer experience through new digital support systems and AI integration [7][8] - The early access launch of Dexcom Smart Basal aims to improve outcomes for Type 2 diabetes management [8] Market Data and Key Metrics Changes - The international business showed strength, particularly in Germany, the United Kingdom, and France, with France being one of the fastest-growing markets due to Type 2 access expansion [16] - The company anticipates that international market opportunities could surpass those in the U.S. over time [11] Company Strategy and Development Direction - The company aims to be the premier glucose sensing solution, focusing on sensor accuracy, reliability, and connectivity [6] - Strategic priorities include enhancing customer experience, expanding international market share, and driving growth through product innovation [10][11] - The company plans to introduce new products in 2026, including Stelo and a new CGM system for international markets [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in metabolic health management and the impact of upcoming Medicare coverage for Type 2 non-insulin users [24][26] - The company expects total revenue for 2026 to be in the range of $5.16 billion to $5.25 billion, reflecting growth of 11%-13% [19][20] - Management highlighted the importance of maintaining gross margin improvements and operational efficiencies while investing in new facilities [20][47] Other Important Information - The company has surpassed $1 billion in free cash flow for the first time in 2025 [19] - An Investor Day is planned for May 2026 to provide further details on the company's outlook [13] Q&A Session Summary Question: Discussion on the company's glucose sensing journey and market potential - Management believes the company is in the early stages of addressing metabolic health issues, with significant growth opportunities in Type 2 coverage expected in the next 12-24 months [24][26] Question: Inquiry about CMS coverage for Type 2 non-insulin users - Management is optimistic about upcoming CMS coverage decisions and is preparing for potential impacts on market access [30][33] Question: Impact of the 15-day product rollout on margins and new markets - The 15-day product is expected to contribute to margins over time, with significant opportunities for international expansion [36][39] Question: Discussion on operating expenses and investments - Increased operating expenses are primarily due to investments in the new Ireland manufacturing facility, which will enhance future production capabilities [46][47] Question: Utilization rates among different user segments - Utilization rates remain stable across various user segments, with high engagement expected to drive further growth [51][52] Question: Revenue outlook and new patient dynamics for 2026 - Revenue growth will depend on patient retention, utilization, and pricing strategies, with a focus on maintaining a stable user base [56][60] Question: Stability of the U.S. sensor uptake trends - Management noted improvements in sensor deployment and stable user retention, contributing to positive sell-through trends [64][66] Question: Pricing dynamics related to Medicare coverage - Pricing strategies will be influenced by competitive bidding processes, with expectations for stable pricing amidst increased volume [72][74] Question: International market growth strategies - The company plans to deepen its presence in existing markets and expand into new regions, with a focus on generating evidence to support market access [80][82]

Dexcom earnings Q4 2025 Safe harbor statement This presentation contains "forward - looking statements" that are based on our management's beliefs and assumptions and on inform ation available to management as of February 12, 2026. We intend for such forward - looking statements to be covered by the safe harbor provisions fo r forward - looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Forward - looking statements include informatio n concerning our possible or assum ...

Core Insights - Dexcom (DXCM) is launching a nationwide AI-driven upgrade to its Stelo platform, enhancing users' understanding of glucose health and supporting long-term wellness goals [2][6] - The upgrade includes a nutrition database with over one million food entries, improving the Smart Food Logging feature and providing detailed macro- and nutrient-level breakdowns for logged meals [2][8] Company Developments - The new features will support various meal-logging methods such as text search, barcode scanning, and photo capture, streamlining the glucose tracking experience [3][4] - The updated Smart Food Logging functionality and Daily Insights tools will be available through upcoming iOS and Android app updates [3][4] - Management indicated that the enhancements are a response to user feedback aimed at simplifying nutrition tracking and reducing barriers to informed dietary choices [4] Market Positioning - The expanded Stelo offerings are expected to strengthen Dexcom's competitive position in the personal and preventive health market by increasing user engagement with AI-enabled nutrition analytics [6] - By broadening the Stelo platform's utility beyond glucose sensing to integrated lifestyle guidance, Dexcom enhances its value proposition for both existing and new customers [6] User Impact - Users reported improved dietary behaviors, physical activity, and weight-management habits after 30 days of using Stelo, indicating that enhanced insights into food-related glucose responses may support more effective metabolic health management [11][12] - The redesigned Daily Insights feature will provide personalized recommendations based on prior-day glucose, activity, nutrition, and sleep data, leveraging AI for adaptive guidance [10] Industry Outlook - The glucose biosensors market was valued at $10.71 billion in 2025 and is projected to grow at a CAGR of 8.9% through 2034, driven by increasing diabetes prevalence and technological advancements [13]

2025 Performance & 2026 Outlook - Preliminary 2025 revenue is expected to be approximately $4662 billion, representing organic growth of ~15%[31] - The active Dexcom base grew by 20%+[31] - Revenue for 2026 is projected to be between $516 billion and $525 billion, representing growth of ~11-13%[33] - Non-GAAP gross margin is expected to be ~63-64% in 2026[34] - Non-GAAP operating margin is expected to be ~22-23% in 2026[34] Market & Product Expansion - Approximately 40% of US adults have prediabetes[13] - Dexcom CGM has powered over 25 million patient years on automated insulin delivery[55] - Dexcom G7 15 Day has an updated algorithm with 80% MARD[56] - Stelo generated ~$130 million in revenue in 2025[72] Financial Expectations - The company expects to generate over $1 billion of free cash flow in 2026[89] - Adjusted EBITDA is expected to be greater than $15 billion[88]

Group 1 - DexCom Inc. has been upgraded by Morgan Stanley to Overweight from Equal Weight with a new price target of $75, reflecting an increase from $63, as the company is overcoming operational challenges and its stock is at historical lows [1] - Evercore ISI initiated coverage of DexCom with an In Line rating and a price target of $68, citing concerns over product quality, manufacturing challenges, and competitive threats that may hinder market share growth through 2026 [2] - DexCom announced FDA clearance for Dexcom Smart Basal, the first CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes, aimed at simplifying insulin management and addressing barriers to therapy [3] Group 2 - DexCom Inc. specializes in designing, developing, and commercializing continuous glucose monitoring (CGM) systems both in the US and internationally [4]

Core Insights - DexCom has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, Dexcom Smart Basal, specifically for adults with Type 2 diabetes using glargine U-100 long-acting insulin therapy [1][8] - The software will utilize data from DexCom's G7 15 day CGM sensor to provide personalized daily insulin dose recommendations, enhancing the effectiveness of long-acting insulin therapy [2][9] - Despite the FDA clearance, DexCom's stock has declined by 23.2% this year, contrasting with the industry's growth of 0.6% and the S&P 500's gain of 13.5% [3] Product Details - Dexcom Smart Basal is the first titration software that integrates with a CGM sensor to optimize basal insulin doses, starting with an initial dose set by healthcare providers [1][6] - The software analyzes CGM readings to provide personalized recommendations, adjusting doses based on glucose levels and offering alerts for low glucose to prevent hypoglycemic episodes [9][10] - The feature is expected to improve adherence to insulin therapy and reduce the workflow for healthcare providers by minimizing manual input and office visits [10] Market Performance - Following the FDA clearance, DexCom's stock fell by 0.7% on November 19, indicating ongoing pressure on gross margins despite the positive regulatory news [3][4] - The introduction of Dexcom Smart Basal is anticipated to boost demand for the G7 15 day sensor among Type 2 diabetes patients [4] Competitive Landscape - DexCom currently holds a Zacks Rank of 3 (Hold), while other medical stocks like Medpace Holdings, Globus Medical, and Masimo have higher rankings, indicating stronger performance in the market [11] - Medpace has shown a significant earnings growth rate of 17.1% for 2025, outperforming the industry average of 16.6% [12] - Globus Medical and Masimo also reported strong earnings, with adjusted EPS exceeding consensus estimates, highlighting competitive performance in the medical sector [12][13]

Core Insights - DexCom, Inc. has received FDA clearance for Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy [1] - The Dexcom Smart Basal will utilize data from the Dexcom G7 15 Day sensor and logged doses to provide personalized daily recommendations for optimizing long-acting insulin doses [1] Company Summary - DexCom, Inc. is recognized as the global leader in glucose biosensing technology [1] - The introduction of Dexcom Smart Basal represents a significant advancement in diabetes management, specifically targeting adults with Type 2 diabetes [1] Industry Impact - The FDA clearance of Dexcom Smart Basal is expected to enhance the management of Type 2 diabetes, potentially improving patient outcomes through personalized insulin dosing [1]